PUBLISHER: DelveInsight | PRODUCT CODE: 1083585
PUBLISHER: DelveInsight | PRODUCT CODE: 1083585
DelveInsight's, 'Migraine-2032' report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Migraine is ranked globally as the seventh most disabling disease among all diseases (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among all neurological disorders.
It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, yet in one-third of migraine attacks, both sides are found to be affected.
Migraine is classified by the nature of the attack and its frequency as chronic and episodic migraine. Episodic migraine is characterized by those with migraine who have 0-14 headache days per month, while chronic migraine is characterized by 15 or more headache days per month.
Migraine remains undiagnosed and undertreated in at least ~ 50% of patients, and less than 50% of migraine patients consult a physician.
Treatment can be acute or preventive. Acute treatment is initiated during an attack to alleviate pain and disability and to stop the progression of the attack. Preventive treatment is used when there exists a known headache trigger, such as exercise or sexual activity, and for patients who have limited time exposure to a trigger, such as high-altitude ascent or menstruation.
The overall dynamics of the Migraine market is anticipated to change in the coming years owing to the expected launch of emerging therapies and others are developing treatments for Migraine.
The Migraine epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as Total Prevalence of Migraine, Prevalent Cases of Migraine based on severity, Gender specific Prevalence of Migraine, and Diagnosed Cases of Chronic and Episodic Migraine. The report includes the prevalent scenario of Migraine in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Migraine epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent population of Migraine associated in the 7MM countries was estimated to be 118,491,327 cases in 2021 and expected to increase at a CAGR of 0.32% for the study period, i.e., 2019-2032.
As per the estimates, United States has the highest prevalence population of Migraine in the 7MM.
Among the EU5 countries, Germany had the highest prevalent population of Migraine. On the other hand Spain reported the lowest prevalent population. In 7MM, Spain had the lowest number of cases i.e. 9,314,356 cases in 2021.
We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Study Period: 2019-2032.